My dad died from an inoperable cancerous brain tumor in 1984. I am hoping that 27 years later researchers may finally be on the right track.
GOLDEN, Colo.--(Business Wire)--
Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances
in its adult stem cell products and technology with application to cell-based
therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer,
we are reminded of such aggressive cancers without effective treatment.
Cancer stem cells are thought to generate cancerous tumors, and while some of
these tumor cells are destroyed by chemotherapy and radiation, cancer stem cells
resist these treatments causing recurrences and metastasis of cancer following
standard therapy. For example, glioblastoma tumors underlying Senator Kennedy`s
brain cancer may arise from cancer stem cells that resist conventional
treatments. Additional research shows that certain adult stem cells migrate to
cancer stem cells and may be used to carry toxic agents to selectively eradicate
cancer stem cells thereby providing novel cellular therapy specifically targeted
to cancer-causing cells. Further development of stem cell therapy may allow
treatment of presently untreatable cancer and also have more widespread
applications to prevention and treatment of cancer.
Vitro`s proprietary stem cell technology and products, now subject to pending
patent protection, may lead to novel cell therapy for cancer. The Company is
pursuing suitable strategic partners to commercialize these novel therapeutic
products. Furthermore, the Company has also commercialized various modified stem
cell lines and related products to support cancer stem cell research including
the development of new methods to target the selective eradication of cancer
stem cells, which is essential to therapeutic efficacy. These products and other
tools for use in stem cell research are now commercially available
(http://www.vitrobiopharma.com/).
Dr. Rice, a member of Vitro`s SAB and a University of Colorado cancer researcher
said, "Cellular-mediated destruction of cancer stem cells represents a promising
new avenue for the development of effective treatments that specifically target
cancer stem cells. Vitro has developed an exciting portfolio of products to
advance research in this field, which is one of the few approaches to show
promise against intractable cancers such as most forms of brain cancer.
Additionally, Vitro`s patent pending technology for cancer therapy represents an
exciting and novel approach to the selective eradication of cancer stem cells
that could usher in new promise in the fight against cancer."
GOLDEN, Colo.--(Business Wire)--
Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances
in its adult stem cell products and technology with application to cell-based
therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer,
we are reminded of such aggressive cancers without effective treatment.
Cancer stem cells are thought to generate cancerous tumors, and while some of
these tumor cells are destroyed by chemotherapy and radiation, cancer stem cells
resist these treatments causing recurrences and metastasis of cancer following
standard therapy. For example, glioblastoma tumors underlying Senator Kennedy`s
brain cancer may arise from cancer stem cells that resist conventional
treatments. Additional research shows that certain adult stem cells migrate to
cancer stem cells and may be used to carry toxic agents to selectively eradicate
cancer stem cells thereby providing novel cellular therapy specifically targeted
to cancer-causing cells. Further development of stem cell therapy may allow
treatment of presently untreatable cancer and also have more widespread
applications to prevention and treatment of cancer.
Vitro`s proprietary stem cell technology and products, now subject to pending
patent protection, may lead to novel cell therapy for cancer. The Company is
pursuing suitable strategic partners to commercialize these novel therapeutic
products. Furthermore, the Company has also commercialized various modified stem
cell lines and related products to support cancer stem cell research including
the development of new methods to target the selective eradication of cancer
stem cells, which is essential to therapeutic efficacy. These products and other
tools for use in stem cell research are now commercially available
(http://www.vitrobiopharma.com/).
Dr. Rice, a member of Vitro`s SAB and a University of Colorado cancer researcher
said, "Cellular-mediated destruction of cancer stem cells represents a promising
new avenue for the development of effective treatments that specifically target
cancer stem cells. Vitro has developed an exciting portfolio of products to
advance research in this field, which is one of the few approaches to show
promise against intractable cancers such as most forms of brain cancer.
Additionally, Vitro`s patent pending technology for cancer therapy represents an
exciting and novel approach to the selective eradication of cancer stem cells
that could usher in new promise in the fight against cancer."